Shares in Esperion Therapeutics lost more than half of their value after it disclosed a dispute with Daiichi Sankyo on a $300 million milestone payment relating to cholesterol drug Nexletol. The ...

Daiichi Sankyo was however unable to secure approval for that indication in both the US and Europe, setting back its plans for the drug.

Consulting or Advisory Role: Roche/Genentech, Novartis, Lilly, Pfizer, AstraZeneca, MSD Oncology, Daiichi Sankyo Europe GmbH, Seagen, Gilead Sciences, Inc., Medac, Menarini Group ...

AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu in March 2019 and Datroway in July 2020, except in Japan where Daiichi Sankyo maintains ...

Enriqueta Felip Consulting or Advisory Role: AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Roche, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, ...

DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and ...

Just days after President Donald Trump was elected in November, AstraZeneca unvei | AstraZeneca CEO Pascal Soriot is plotting ...

MSD and Daiichi Sankyo have announced first subject dosing in the randomised IDeate-Prostate01 Phase III trial of ifinatamab deruxtecan (I-DXd) against docetaxel in individuals with metastatic ...

The Contrast Media Market is projected to grow at a CAGR of 5-6%. Key factors influencing the contrast media market include ...

Elinzanetant is the first neurokinin-targeted therapy to demonstrate efficacy in reducing vasomotor symptoms (VMS)” — otherwise known as hot flashes — “in women with breast cancer,” Fatima Cardoso, MD ...